- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03500731
Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure
Lung Transplant in Tandem With Bone Marrow Transplant for Combined Lung and Bone Marrow Failure
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Paul Szabolcs, M.D.
- Phone Number: 412-692-5427
- Email: Paul.Szabolcs@chp.edu
Study Contact Backup
- Name: Shawna H McIntyre, RN
- Phone Number: 4126925552 412-692-5552
- Email: mcintyresm@upmc.edu
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15224
- Recruiting
- Children's Hospital of Pittsburgh of UPMC
-
Principal Investigator:
- Paul Szabolcs, MD
-
Contact:
- Shawna H McIntyre, RN
- Phone Number: 412-692-5552
- Email: mcintyresm@upmc.edu
-
Pittsburgh, Pennsylvania, United States, 15214
- Recruiting
- UPMC Presbyterian
-
Contact:
- John McDyer, MD
- Phone Number: 412-648-6161
- Email: mcdyerjf@upmc.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Individuals must meet all of the following criteria in order to be eligible for this study.
- Subject must be able to understand and provide informed consent.
- Male or female, 18 through 60 years old, inclusive, at the time of informed consent.
- Meet criteria for UNOS listing for lung transplantation.
Patients must have evidence of end stage lung disease. Examples of such diseases include but are not limited to:
- Pulmonary Fibrosis
- COPD/Emphysema
Patients must have evidence of bone marrow failure with abnormal low cell count in at least one hematopoietic line, making the patient a poor candidate for long-term immunosuppressive therapy. Eligible patients must meet at least one of the following criteria:
- Unexplained, non-drug induced neutropenia with absolute neutrophils counts of <1500/µL the previous year, confirmed by repeat testing
- Unexplained, non-drug induced thrombocytopenia with mean platelets counts of <100,000/µL the previous year, confirmed by repeat testing
- Unexplained, non-hemolytic anemia, with a hemoglobin level of < 12 g/dL the previous year, confirmed by repeat testing
- GFR ≥45 mL/min/1.73 m2.
- AST, ALT ≤4x upper limit of normal, total bilirubin ≤ 2.5 mg/dL, normal INR, albumin >3.0 g/dL
- Cardiac ejection fraction ≥ 40% or shortening fraction ≥26%.
- Negative pregnancy test for females, unless surgically sterilized.
- All females of childbearing potential and sexually active males must agree to use a FDA approved method of birth control for up to 24 months after BMT or for as long as they are taking any medication that may harm a pregnancy, an unborn child or may cause birth defect.
- Subject will also be counseled regarding the potential risks of infertility following BMT and advised to discuss sperm banking or oocyte harvesting.
Exclusion Criteria:
Individuals who meet any of these criteria are not eligible for this study.
- Inability or unwillingness of a participant to give written informed consent or comply with study protocol.
- Patients who have underlying malignant conditions.
- Patients who have non-malignant conditions not requiring BMT.
- HIV positive by serology or PCR, HTLV positive by serology. If HTLV serology is positive, it will be confirmed by nucleic acid testing (NAT). If HTLV NAT is negative, subject will remain eligible regardless of HTLV serology result.
- Females who are pregnant or who are lactating.
- Allergy to DMSO or any other ingredient used in the manufacturing of the stem cell product.
- Uncontrolled pulmonary infection, as determined by radiographic findings and/or significant clinical deterioration. NOTE: Pulmonary colonization with multiple organisms is common and will not be considered an exclusion criterion.
- Uncontrolled infection, as determined by the appropriate imaging and/or confirmatory testing e.g. blood cultures, PCR testing, etc.
- Recent recipient of any licensed or investigational live attenuated vaccine(s) within 4 weeks of transplant.
- Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Lung and Bone Marrow Transplantation
All patients will undergo a cadaveric, partially HLA-matched lung transplantation followed by a CD3+/CD19+ depleted BMT from the same donor. In this study, the investigators will use a ≥1/6 HLA-matched T cell depleted bone marrow transplantation from a cadaveric organ donor with an identical ABO blood type as the recipient. Prior to transplantation, the marrow will be negatively selected for CD3/CD19 using a CliniMACS® depletion device. Subjects will undergo lung transplantation utilizing standard induction regimens selected by the CO-PIs based on the subject's underlying comorbidities and allosensitization. Rituximab may be initiated prior to the lung transplantation with tacrolimus as the ongoing maintenance immunosuppression. Subjects will undergo BMT utilizing CD3+/CD19+-depleted bone marrow with bone marrow conditioning beginning no less than 8 weeks after lung transplantation. Bone marrow will be recovered alongside solid organs and will be processed and cryopreserved. |
Transplantation Conditioning
Other Names:
Transplantation Conditioning
Other Names:
Transplantation Conditioning
Negative selection for CD3/CD19 will be performed on CliniMACS® depletion device and given at time no less than 8 weeks post lung transplantation
Transplantation Conditioning
Other Names:
Transplantation conditioning
Other Names:
Transplantation Conditioning
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Death
Time Frame: Up to 2 years post stem cell transplant
|
How many, if any, patients die
|
Up to 2 years post stem cell transplant
|
Engraftment failure
Time Frame: Up to 2 years post stem cell transplant
|
How many, if any, develop engraftment failure
|
Up to 2 years post stem cell transplant
|
Non-hematologic events
Time Frame: Up to 2 years post stem cell transplant
|
Any Grade 4 event that happens at any time points
|
Up to 2 years post stem cell transplant
|
Hematological events
Time Frame: after 30 days post stem cell transplant
|
Any Grade 4 hematological events
|
after 30 days post stem cell transplant
|
BOS Score
Time Frame: at 1 year post lung transplant
|
Bronchiolitis Obliterans Syndrome (BOS) score based off patient pulmonary function testing.
Graded on scale (BOS0 to BOS3), BOS0 having a better outcome then BOS3
|
at 1 year post lung transplant
|
T-cell Chimerism
Time Frame: at 12 months post stem cell transplant
|
The number of patients who have ≥25% donor T-cell chimerism
|
at 12 months post stem cell transplant
|
Myeloid chimerism
Time Frame: at 12 months post stem cell transplant
|
The number of patients with myeloid disorders who attain ≥ 10% myeloid chimerism
|
at 12 months post stem cell transplant
|
Restoration of blood cell count (in absence of growth factors)
Time Frame: at 12 months post stem cell transplant
|
Absolute neutrophil count (ANC)≥1000 per microliter of blood, platelets ≥50000 per microliter of blood and hematocrit ≥8 grams per deciliter of blood
|
at 12 months post stem cell transplant
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility of patients able to proceed to BMT within 6 months following lung transplantation
Time Frame: Up to 2 years post stem cell transplant
|
The number of patients who are able to proceed to BMT within 6 months following lung transplantation
|
Up to 2 years post stem cell transplant
|
Independence
Time Frame: up to 2 years post stem cell transplant
|
The number of patients who are able to be independent from transfusions and growth factors for at least 7 days
|
up to 2 years post stem cell transplant
|
Independence
Time Frame: Up to 2 years post stem cell transplant
|
The number of patients who are able to be independent from transfusions and growth factors for at least 1 month
|
Up to 2 years post stem cell transplant
|
Tolerance development to both host and pulmonary grafting
Time Frame: Up to 2 years post stem cell transplant
|
Development of tolerance to both the host and pulmonary graft
|
Up to 2 years post stem cell transplant
|
Long-term complications
Time Frame: Up to 2 years post stem cell transplant
|
Long-term complications of combined solid organ and BMT
|
Up to 2 years post stem cell transplant
|
Acute cellular rejection
Time Frame: Up to 2 years post stem cell transplant
|
The number of patients who develop acute cellular rejection
|
Up to 2 years post stem cell transplant
|
Acute graft-versus-host-disease (GVHD)
Time Frame: Up to 2 years post stem cell transplant
|
The number of patients who develop acute graft-versus-host-disease (GVHD)
|
Up to 2 years post stem cell transplant
|
Chronic graft-versus-host-disease (GVHD)
Time Frame: Up to 2 years post stem cell transplant
|
The number of patients who develop chronic graft-versus-host-disease (GVHD)
|
Up to 2 years post stem cell transplant
|
Ability to withdrawal immunosuppression
Time Frame: By 1 year post stem cell transplant
|
The number of patients who are able to start immunosuppression withdrawal.
|
By 1 year post stem cell transplant
|
Time to withdraw immunosuppression
Time Frame: Up to 2 years post stem cell transplant
|
Time from BMT to withdrawal of immunosuppression
|
Up to 2 years post stem cell transplant
|
Prophylactic antimicrobial drugs
Time Frame: Up to 2 years post stem cell transplant
|
Time from BMT to independence for prophylactic antimicrobial drugs
|
Up to 2 years post stem cell transplant
|
Treatment antimicrobial drugs
Time Frame: up to 2 years post stem cell transplant
|
Time from BMT to independence from treatment antimicrobial drugs
|
up to 2 years post stem cell transplant
|
Chronic lung allograft dysfunction
Time Frame: 1 year post lung transplant
|
The number of patients who develop chronic lung allograft dysfunction post lung transplant for all subjects, lung only and lung +stem cell transplant.
|
1 year post lung transplant
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pace of immune reconstitution
Time Frame: Up to 2 years post stem cell transplant
|
The pace of immune reconstitution, systemically and in mucosal surfaces
|
Up to 2 years post stem cell transplant
|
Mixed chimerism
Time Frame: at Months 1, 3, 6 and 12 post stem cell transplant
|
The number of patients who have the incidence of mixed chimerism (.5% host cells)
|
at Months 1, 3, 6 and 12 post stem cell transplant
|
In vitro immune tolerance
Time Frame: Up to 2 years post stem cell transplant
|
The number of patients who have in vitro immune tolerance
|
Up to 2 years post stem cell transplant
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Respiratory Tract Diseases
- Lung Diseases
- Disease Attributes
- Bone Marrow Diseases
- Hematologic Diseases
- Lung Diseases, Obstructive
- Pulmonary Disease, Chronic Obstructive
- Lung Diseases, Interstitial
- Chronic Disease
- Fibrosis
- Pulmonary Emphysema
- Emphysema
- Pulmonary Fibrosis
- Idiopathic Pulmonary Fibrosis
- Bone Marrow Failure Disorders
- Pancytopenia
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Antineoplastic Agents, Immunological
- Antisickling Agents
- Rituximab
- Fludarabine
- Hydroxyurea
- Thiotepa
- Alemtuzumab
Other Study ID Numbers
- PRO17110400
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Idiopathic Pulmonary Fibrosis
-
St. Antonius HospitalZonMw: The Netherlands Organisation for Health Research and Development; Boeringer...RecruitingPulmonary Fibrosis Idiopathic FamilialNetherlands
-
Wake Forest University Health SciencesMayo Clinic; The University of Texas Health Science Center at San AntonioCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
Sheba Medical CenterUnknownIDIOPATHIC PULMONARY FIBROSISIsrael
-
Theravance BiopharmaTerminatedIdiopathic Pulmonary Fibrosis (IPF)United Kingdom
-
University of California, San FranciscoCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
BiogenCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
Liminal BioSciences Ltd.CompletedIdiopathic Pulmonary Fibrosis (IPF)Canada
-
Bristol-Myers SquibbCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
Angion Biomedica CorpNot yet recruitingIdiopathic Pulmonary Fibrosis (IPF)
-
Xfibra, Inc.Not yet recruitingIdiopathic Pulmonary Fibrosis (IPF)
Clinical Trials on Rituximab
-
Children's Oncology GroupNational Cancer Institute (NCI)Active, not recruitingEBV-Related Post-Transplant Lymphoproliferative Disorder | Monomorphic Post-Transplant Lymphoproliferative Disorder | Polymorphic Post-Transplant Lymphoproliferative Disorder | Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder | Recurrent Polymorphic Post-Transplant Lymphoproliferative... and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingRecurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Grade 3a Follicular... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingAnn Arbor Stage I Grade 1 Follicular Lymphoma | Ann Arbor Stage I Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 1 Follicular Lymphoma | Ann Arbor Stage II Grade 2 Follicular LymphomaUnited States
-
National Cancer Institute (NCI)CompletedAnn Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma | Ann Arbor Stage II Grade 3 Non-Contiguous... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingRecurrent Small Lymphocytic Lymphoma | Prolymphocytic Leukemia | Recurrent Chronic Lymphocytic LeukemiaUnited States
-
National Cancer Institute (NCI)Celgene CorporationActive, not recruitingAnn Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma | Ann Arbor Stage II Grade 3 Non-Contiguous... and other conditionsUnited States
-
PfizerCompletedRheumatoid ArthritisUnited States, Australia, Canada, Israel, Mexico, Colombia, Germany, Russian Federation, South Africa, United Kingdom
-
Mabion SAParexelWithdrawn
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingChronic Lymphocytic Leukemia/Small Lymphocytic LymphomaUnited States